-
| ISIN | PLONCTH00011 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | WAR |
| CurrencyCode | PLN |
| Market Cap | 422M |
|---|---|
| PE Ratio | 7.11 |
| Target Price | 55.55 |
| Dividend Yield | 0.0% |
| Beta | 2.62 |
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OAT.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025